공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

비소세포 폐암(NSCLC) : 역학 예측(-2029년)

Non-Small Cell Lung Cancer - Epidemiology Forecast to 2029

리서치사 GlobalData
발행일 2020년 12월 상품 코드 979399
페이지 정보 영문 58 Pages
가격
US $ 3,995 ₩ 4,640,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 9,281,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 13,921,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


비소세포 폐암(NSCLC) : 역학 예측(-2029년) Non-Small Cell Lung Cancer - Epidemiology Forecast to 2029
발행일 : 2020년 12월 페이지 정보 : 영문 58 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 주요 8개국의 비소세포 폐암(NSCLC) 18세 이상 진단 사례는 2019년 79만 4,999 건을 나타냈습니다. 지역별로 보면, 중국 도시가 301,036건으로 최대 점유율을 차지했고, 스페인이 29,977건으로 가장 낮은 점유율을 나타냈습니다. 또한 예측기간 중에는 3.01%의 연평균 복합 성장률(CAGR)을 나타내고, 2029년 진단 사례는 103만 4554건으로 증가할 전망입니다.

세계 주요 8개국의 비소세포 폐암(NSCLC: Non-Small Cell Lung Cancer) 시장을 조사했으며, 질환 개요, 병인/병태생리, 발병 추이와 예측, 각종 구분별 분석, 향후 전망 등의 정보를 정리하여 전해드립니다.

제1장 목차

제2장 개요

제3장 역학

  • 질환의 배경
  • 위험인자/동반질환
  • 세계 동향과 역사적 동향
  • 예측 조사 방법
  • 역학 예측
    • 진단 사례
    • 진단 사례 : 남녀별
    • 진단 사례 : 연령별
    • 진단 사례 : 단계별
    • 진단 사례 : 조직형별
    • 진단 사례 : 게놈 바이오마커, EGFR, KRAS 변이별
    • 진단 사례 : 변이별
    • 5개년 진단 환자수
  • 검토

제4장 부록

LSH 21.01.07

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for NSCLC
  • Table 4: 8MM, Diagnosed Incident Cases of NSCLC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 5: 8MM, Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Immunotherapy and Genomic Biomarkers, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 6: 8MM, Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations, Ages ≥18 Years, Both Sexes, N, 2019

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, 2019 and 2029
  • Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, 2019 and 2029
  • Figure 3: 8MM, Diagnosed Incidence of

Non-Small Cell Lung Cancer - Epidemiology Forecast to 2029

Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world (International Agency for Research on Cancer, 2018). There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Other less common types of lung tumors include lung carcinoid tumors, adenoid cystic carcinomas, lymphomas, and sarcomas. Benign lung tumors such as hamartomas are rare. NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers. SCLC accounts for 10-15% of lung cancers, while carcinoid tumors are the rarest, occurring in fewer than five percent of lung cancers (American Cancer Society, 2016). The majority of lung cancer cases are attributable to smoking. However, a sizable portion of cases occur in non-smokers, implying that genetic components, family history, and environmental exposure also play a prominent role in the development of the disease (American Cancer Society, 2016).

In 2019, there were 794,999 diagnosed incident cases of NSCLC in men and women combined, ages 18 years and older, in the 8MM. Urban China accounted for the largest share of these cases with 301,036 diagnosed incident cases, while Spain accounted for the smallest share with 29,977 cases in 2019. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of NSCLC to 1,034,554 cases in 2029 in the 8MM at an Annual Growth Rate (AGR) of 3.01% during the forecast period. In 2019, there were 1,060,302 five-year diagnosed prevalent cases of NSCLC in men and women combined, ages 18 years and older, in the 8MM. Urban China accounted for the largest share of these cases with 354,667 cases, while Spain accounted for the smallest share with 25,831 cases in 2019. The five-year diagnosed prevalent cases of NSCLC will increase to 1,370,422 cases in 2029 at an AGR of 2.92% during the forecast period.

Scope

  • The Non-Small Cell Lung Cancer (NSCLC) Epidemiology Report provides an overview of the risk factors and the global and historical trends for NSCLC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes diagnosed incident cases and five-year diagnosed prevalent cases of NSCLC in these markets from 2019-2029.
  • The incident cases are further segmented by sex and age (18-39 years, 40-59 years, 60-79 years, and 80 years and older), by cancer stage at diagnosis (stages IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV), and by cancer histology subtype (non-squamous cell carcinoma [adenocarcinoma, large cell carcinoma, and others] and squamous cell carcinoma). Diagnosed incident cases of non-squamous cell carcinoma are further segmented by mutations, specifically immunotherapy biomarkers, and genomic biomarkers. Diagnosed incident cases of non-squamous cell carcinoma EGFR are segmented by subtypes. Diagnosed incident cases of non-squamous cell carcinoma KRAS were segmented by subtypes. The diagnosed incident cases of squamous cell carcinoma are segmented by mutations.
  • The NSCLC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The NSCLC Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global NSCLC market.
  • Quantify patient populations in the global NSCLC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for NSCLC therapeutics in each of the markets covered.
  • Understand magnitude of NSCLC by stage at diagnosis, histology types, and biomarkers.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Non-Small Cell Lung Cancer: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Incident Cases of NSCLC
    • 3.4.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 3.4.5 Diagnosed Incident Cases of NSCLC by Histological Types
    • 3.4.6 Mutations Among Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma
    • 3.4.7 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 3.5 Epidemiological Forecast for NSCLC, 2019-2029
    • 3.5.1 Diagnosed Incident Cases of NSCLC
    • 3.5.2 Sex-Specific Diagnosed Incident Cases of NSCLC
    • 3.5.3 Age-Specific Diagnosed Incident Cases of NSCLC
    • 3.5.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 3.5.5 Diagnosed Incident Cases of NSCLC by Histological Type
    • 3.5.6 Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Mutations: Genomic Biomarkers, EGFR and KRAS Mutations
    • 3.5.7 Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations
    • 3.5.8 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 COVID-19 Impact
    • 3.6.3 Limitations of the Analysis
    • 3.6.4 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
Back to Top
전화 문의
F A Q